Nizatidine is indicated for the treatment for gastric and duodenal ulcers.
It blocks one of the chemicals (histamine) that stimulates the production of stomach acid.
Following the approval, Glenmark Generics, a subsidiary of Glenmark Pharmaceuticals, expects to begin marketing of the drug soon.